Nature Reviews Gastroenterology & Hepatology, Published online: 13 November 2026; doi:10.1038/s41575-026-01284-8 Obesity and inflammatory bowel disease are increasingly recognized as interconnected inflammatory and metabolic disorders. New insights into glucagon-like peptide-1 signalling highlight the role of phosphodiesterase 4 in energy balance. Although phosphodiesterase 4 inhibitors have previously been studied in inflammatory bowel disease, their potential to address both gut inflammation and obesity remains unexplored.
Laurent Peyrin-Biroulet, Sailish Honap. PDE4 inhibition at the crossroads of IBD and obesity. // Nature Reviews Gastroenterology & Hepatology. – 2026. – DOI: 10.1038/s41575-026-01284-8. – URL: https://www.nature.com/articles/s41575-026-01284-8
Laurent Peyrin-Biroulet & Sailish Honap (2026). PDE4 inhibition at the crossroads of IBD and obesity. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-026-01284-8
Laurent Peyrin-Biroulet and Sailish Honap. “PDE4 inhibition at the crossroads of IBD and obesity.” Nature Reviews Gastroenterology & Hepatology, 2026. doi:10.1038/s41575-026-01284-8.
@article{PeyrinBiroulet2026,
title = {PDE4 inhibition at the crossroads of IBD and obesity},
author = {Peyrin-Biroulet, Laurent and Honap, Sailish},
journal = {Nature Reviews Gastroenterology \& Hepatology},
year = {2026},
doi = {10.1038/s41575-026-01284-8},
url = {https://www.nature.com/articles/s41575-026-01284-8}
}
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05030-x Comment on: ‘Association of accelerometer-monitored physical activity with incident cataract: epidemiological and genetic evidence’
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05032-9 NAION during incretin-based therapy: an optic nerve head still adapted to hypertension
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05016-9 Comparing refractive errors in CACNA1F and CABP4 -associated disease in a UK cohort
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05018-7 Comment on: ‘Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease’